Mark Fortner
@markfortner.bsky.social
CEO @ https://aspen.bio, Helping R&D Leaders Transform Their Drug Discovery Operations with AI & Automation |Creator of The Ring of Fire Portfolio & Project Management Framework
Abcuro raises $66M to fund a Phase 3 trial in a muscle-weakening condition. endpoints.news/abcuro-gets-...
Abcuro gets $66M for Phase 3 in muscle-weakening condition
Abcuro has collected $66 million a few months after saying its sole drug missed the mark in inclusion body myositis, but had found hope in a subset of patients with less severe forms.
endpoints.news
MapLight hits pause on its programs; ADC Therapeutics weighs Zynlonta's future. endpoints.news/maplight-pre...
MapLight presses the pause button; ADC Therapeutics considers what to do with Zynlonta
MapLight pauses preclinical work to focus on ML-007C-MA for schizophrenia; ADC Therapeutics weighs Zynlonta's future after FDA flags safety concerns in LOTIS-5 trial.
endpoints.news
The Pipeline Drug Discovery Platform is your mission control for drug discovery programs. Helping you manage plan, manage and execute #DrugDiscovery programs, create protein target forms, create compound libraries and screen them. bit.ly/3TUtOmj #PM #PPM
Give us 10 minutes and we'll show you how Digital Transformation with AI and Automation can change your drug discovery operations. bit.ly/4blEtN6 #DrugDiscovery #DigitalTransformation #AI #automation.
41 years ago, Carl Sagan gave a clear and elegant explanation of the science behind global warming.
Chemicals regulation in the UK needs to change – and a new BBC series set to air on Monday is proof why. Buried with Michael Sheen will lift the lid on a pollution scandal and serves as a reminder of how important effective chemicals management is. Learn more: rsc.li/3Uj2Ncp #ChemSky
Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer www.cell.com/cancer-cell...
Lawnmower-like enzyme rewinds decades of molecular aging in humans | #aging
Lawnmower-like Enzyme Rewinds Decades of Molecular Aging in Human Tissue | The Scientist
An engineered enzyme cleaved and repaired age-related protein damage in human tissue, which was long thought to be irreversible in a proof-of-concept study.
the-scientist.com
July's biopharma layoffs affect 466 employees, a 94% year over year drop | #biotech
July's biopharma layoffs affect 466 employees, a 94% year-over-year drop
Last month, biopharmas cutting or planning to cut their workforces included Amgen, GSK and Novartis, with Novartis’ layoffs affecting the most people.
biospace.com
Formation Bio taps Biogen, Pfizer asylum to ramble R&Ds 'boring middle' | #biotech
Formation Bio taps Biogen, Pfizer alum to tackle R&D’s ‘boring middle’
Dr. Michael Ehlers bets AI can ease the clinical-development bottleneck — but scaling Formation Bio’s pipeline will also require human judgment.
pharmavoice.com
Our sun is capable of storms far bigger than we’ve ever recorded. Studying the world’s oldest trees suggests we could be due one of these gargantuan events soon
How ancient trees are warning us about the next enormous solar storm | New Scientist
Our sun is capable of storms far bigger than we’ve ever recorded. Studying the world’s oldest trees suggests we could be due one of these gargantuan events soon
newscientist.com
A company has created dogs that do not have the main protein that provokes allergies, and hopes to get approval to start selling them
Gene-edited dogs lack the protein that causes allergies | New Scientist
A company has created dogs that do not have the main protein that provokes allergies, and hopes to get approval to start selling them
newscientist.com
PTC Therapeutics and Lilly are buying pieces of the bankrupt Sangamo for up to $264M, with PTC taking the Fabry disease gene therapy and planning an FDA filing this year.
PTC Therapeutics, Lilly to buy up bits of Sangamo in bankruptcy auction
The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264 million following an auction procedure.
endpoints.news
Pharmalot.. Pharmalittle.. Good Morning: We’re reading about California insulin sales, a Moderna patent battle, and more.. statnews.com/pharmalot/20... #pharma #insulin #California #patent #obesity #weight #antibiotic #hypertension #Lilly #Moderna #NovoNordisk
Pharmalittle: We're reading about California insulin sales, a Moderna patent battle, and more
Seven months after the launch of its own low-cost insulin brand, California has distributed more than 120,000 five-pen packs of insulin glargine priced at $55 each
statnews.com
Does big pharma’s calculus around drug development change if the bulk of the biopharma industry ends up shifting to China? Pfizer’s Andrew Baum said probably not — but that investment in the US would still matter.
Karyopharm has until Sept. 10 to raise cash or risk defaulting on its term loan, clouding its plan to expand its cancer drug Xpovio into a new indication.
Karyopharm has a month left to salvage its cancer expansion plans
Karyopharm Therapeutics faces default by Sept. 10 on its term loan. CEO Richard Paulson seeks financing as cancer drug Xpovio's future hangs in balance.
endpoints.news
Taiho and Cullinan's oral lung cancer drug hit its goal in a Phase 3 front-line trial, setting up a challenge to J&J's Rybrevant.
Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
Taiho and Cullinan's zipalertinib hits its Phase 3 goal in lung cancer, setting up a fight with J&J's Rybrevant.
endpoints.news
Scientists once believed they could pinpoint the moment when humans first appeared. But as new fossils have filled in our evolutionary history, that defining moment has begun to disappear – replaced by a far stranger picture of what it means to be human
The Line Between Human and Ape Doesn't Exist
m.youtube.com
Cytokinetics sues Bristol-Myers Squibb over heart drug patent www.bizjournals.com/sanfrancisco...
Cytokinetics files patent lawsuit against Bristol-Myers Squibb over heart drug - San Francisco Business Times
Heart attack: A Bay Area company is suing giant Bristol-Myers Squibb to protect an important cardiac drug.
bizjournals.com
Pfizer's former chemistry whizz debuts Khartis Therapeutics with $95M for thyroid eye disease pill | #biotech
Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pill
Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer chemist has unveiled his latest venture. | Three years after Robert Hoffman sold XinThera to Gilead, the veteran Pfizer che...
fiercebiotech.com
Genetic tests of mammoth remains have found a stark contrast in the sex ratio between sites where the animals died naturally and those associated with humans, offering hints about how our ancestors hunted
Woolly mammoths butchered by humans were mostly female | New Scientist
Genetic tests of mammoth remains have found a stark contrast in the sex ratio between sites where the animals died naturally and those associated with humans, offering hints about how our ancestors hunted
newscientist.com
The Pipeline Drug Discovery Platform is your mission control for drug discovery programs. Helping you manage plan, manage and execute #DrugDiscovery programs, create protein target forms, create compound libraries and screen them. bit.ly/3TUtOmj #PM #PPM
Skylark bio kicks off new gene therapy trial for deafness | #biotech
Skylark Bio kicks off new gene therapy trial for deafness
Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.
statnews.com
The US has spent the last decade spending more and more money to develop less innovative medicines, says Jake Becraft, Strand Therapeutics CEO. Any response to China’s increasing biotech edge has to include reforms that address that root issue, he said during Endpoints’ China event.
Epicrispr raised $90M to push its epigenetic editing therapy toward an FDA filing, after early data showed the first muscle gains ever reported in an FSHD trial.
Epicrispr secures $90M after early data on epigenetic FSHD treatment
Epicrispr has raised a Series C round after sharing promising early data for EPI-321, a potential new way to treat facioscapulohumeral muscular dystrophy.
endpoints.news
Researchers writing in Nature Biotechnology argue Exelixis is product-hopping off its $2.9B cancer drug with a successor that's only trivially different, as the original loses patent protection this month. John Carroll has the story.
Did Exelixis use a 'trivial' modification to its cash cow to product-hop past a patent cliff? These researchers think so
Exelixis CEO Michael Morrissey faces criticism from researchers including Mark Ratain, who allege zanzalintinib is a
endpoints.news
On Monday, President Trump signed an executive order that calls for reducing the number of recommended childhood vaccines. History has shown how plagues from the past can roar back when trust in shots — or access to them — falters. Revisit our March investigation:
How Robert F. Kennedy Jr.’s Vaccine Agenda Risks a Resurgence of Deadly Childhood Plagues
The health secretary is spreading doubts about vaccine safety and considering changes that could prompt manufacturers to flee the U.S. market. History has shown how plagues from the past can roar back...
propublica.org
Could changing your gut bacteria make cancer treatments finally work better? www.futura-sciences.com/en/could-cha...
Could changing your gut bacteria make cancer treatments finally work better? - Futura-Sciences
Nanoparticle chemotherapy encapsulates anti-cancer drugs inside microscopic carriers, such as liposomes, polymers, or albumin particles, to minimize damage to healthy tissue. While currently used to t...
futura-sciences.com
